Adaptimmune raises $100M via registered direct offering

Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $100 million through the sale of 10 million ADSs at $10 in a registered direct offering to Matrix Capital Management, New Enterprise Associates and Syncona Ltd. (LSE:SYNC). The price is a 9% discount to Adaptimmune’s close of $10.94 on Sept. 4, the day before the offering was announced.

Adaptimmune said the offering extends its runway through late 2020...